AbbVie Submits Upadacitinib for Vitiligo Treatment, Potentially First Systemic Therapy for Autoimmune Skin Disease
核心洞察
AbbVie (搜索) has submitted regulatory applications to the FDA and EMA for upadacitinib 15 mg once daily as the first systemic treatment for adult and adolescent patients with non-segmental vitiligo.
The submissions are supported by Phase 3 Viti-Up studies involving 614 patients across 90 global sites, which met co-primary endpoints of 50% total body re-pigmentation and 75% facial re-pigmentation at 48 weeks.
If approved, upadacitinib would address a significant unmet medical need for patients with this chronic autoimmune disease that causes unpredictable white patches and profound psychosocial impact.
AbbVie (搜索) has submitted regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of upadacitinib (RINVOQ) 15 mg once daily for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). If approved, this would mark the first systemic medication available for patients with vitiligo, addressing critical treatment gaps for those living with this chronic, unpredictable autoimmune disease.
The regulatory submissions are supported by data from the Phase 3 Viti-Up clinical studies, which demonstrated that upadacitinib achieved the co-primary endpoints of at least a 50% improvement in total body re-pigmentation (T-VASI 50) and at least a 75% improvement in facial re-pigmentation (F-VASI 75) from baseline at week 48.
Addressing Unmet Medical Need
Non-segmental vitiligo represents one of the most challenging autoimmune skin diseases to manage in clinical practice. NSV, affecting approximately 84% of vitiligo patients, is characterized by symmetrical and bilateral depigmented white patches that are prone to unpredictable progression even after long periods of stability. The condition imposes a significant psychosocial burden, profoundly affecting an individual's confidence, identity, and daily life.
"Many patients experience ongoing frustration due to the unpredictability of non-segmental vitiligo spread and the lack of systemic treatment options that can stabilize disease progression and achieve skin re-pigmentation," said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development at AbbVie (搜索).
Currently, there are no approved systemic medicines for achieving the three primary treatment goals in vitiligo management: disease stabilization, re-pigmentation, and maintaining re-pigmentation.
JAK Inhibition Mechanism
Upadacitinib is an oral JAK inhibitor with greater inhibitory potency for JAK-1 (搜索) relative to JAK-2 (搜索), JAK-3 (搜索), and TYK-2 (搜索) based on enzymatic and cellular assays. The drug targets interferon-γ-driven immune pathways and downstream JAK-STAT signaling that have been implicated in melanocyte destruction in vitiligo. This mechanistic understanding has driven interest in JAK inhibitors as potential disease-modifying agents for the condition.
Christopher Bunick, MD, PhD, Dermatology Times editor-in-chief and associate professor of dermatology at Yale School of Medicine, noted the significance of this development: "It is an exciting day for vitiligo patients and the dermatology field to learn that upadacitinib is taking the next regulatory steps with the FDA and EMA to become the first approved systemic therapy for adolescents and adults experiencing vitiligo."
Comprehensive Phase 3 Program
The Viti-Up clinical studies (NCT06118411) comprised two replicate Phase 3 trials conducted under a single protocol, with each study maintaining independent randomization, investigative sites, data collection, and statistical analyses. A total of 614 patients aged 12 years and older with NSV were enrolled across 90 global sites, with all participants considered candidates for systemic therapy.
During Period A, patients were randomized in a 2:1 ratio to receive either upadacitinib 15 mg once daily or placebo for 48 weeks. Those completing Period A were eligible to enter Period B, a 112-week open-label extension in which all participants received upadacitinib. Combined, the studies allow for evaluation over a total of 160 weeks.
Clinically Meaningful Endpoints
The co-primary endpoints were designed to reflect meaningful clinical improvement, focusing on achievement of Total Vitiligo Area Scoring Index (T-VASI) 50, defined as at least 50% reduction in T-VASI from baseline, and Facial Vitiligo Area Scoring Index (F-VASI) 75, defined as at least 75% reduction in F-VASI from baseline, both at week 48.
Facial involvement was given particular attention given its disproportionate impact on quality of life and patient-reported outcomes. Secondary endpoints evaluated both the magnitude and timing of facial re-pigmentation, including F-VASI 50 at week 48 and F-VASI 75 as early as week 24, providing insight into how quickly visible improvement may occur with systemic therapy.
Regulatory Path Forward
AbbVie (搜索) has reported that the Viti-Up studies met key efficacy objectives, forming the basis for the current regulatory review. The submission represents an important inflection point in vitiligo drug development, signaling the possibility that systemic therapy may soon become part of the therapeutic armamentarium for NSV, particularly for patients with widespread, progressive, or treatment-refractory disease.
Bunick emphasized the clinical significance: "Effective treatments for vitiligo are major unmet need in dermatology, yet upadacitinib's phase 3 trial data for F-VASI and T-VASI response at 48 weeks gives vitiligo patients hope that meaningful improvement is coming soon."
The regulatory review will be crucial in determining whether upadacitinib ultimately alters standard practice, with careful evaluation of both efficacy data and safety considerations that are central to JAK inhibitor use, including infection risk and long-term immunologic effects.